Kristin Haddock, APRN
Payments from drug & device makers
Across 140 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$654
- Novo Nordisk$329
- GSK$256
- Lilly USA, LLC$140
- Astellas Pharma US Inc$129
- Novartis$85
- plus $709 from 23 others
What the payments were for
- Food & beverage$2,302100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $654 |
| Novo Nordisk | 18 | $329 |
| GSK | 17 | $256 |
| Lilly USA, LLC | 9 | $140 |
| Astellas Pharma US Inc | 7 | $129 |
| Novartis | 4 | $85 |
| AstraZeneca | 5 | $84 |
| Dexcom, Inc. | 4 | $65 |
| Pfizer | 4 | $60 |
| Abbott | 3 | $58 |
| Exact Sciences | 3 | $51 |
| Amgen | 2 | $43 |
| Upsher-smith Laboratories LLC | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Merck | 2 | $26 |
| Antares Pharma, Inc. | 2 | $26 |
| Globus Medical | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Inari Medical, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Endogastric Solutions, Inc | 1 | $12 |
How this compares
$2,302 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $66,184 |
| JardianceEmpagliflozin | 47 | $54,766 |
| EliquisApixaban | 44 | $41,442 |
| JanuviaSitagliptin Phosphate | 33 | $38,886 |
| XareltoRivaroxaban | 22 | $29,842 |
| EntrestoSacubitril/Valsartan | 31 | $25,566 |
| MyrbetriqMirabegron | 41 | $24,201 |
| LinzessLinaclotide | 22 | $14,992 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,316 |
| FarxigaDapagliflozin Propanediol | 22 | $13,511 |
| MounjaroTirzepatide | 11 | $11,495 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,184 |
| Atorvastatin Calcium | 610 | $5,678 |
| BrilintaTicagrelor | 11 | $5,495 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $329 | $66,18446 claims |
| PfizerEliquis | $60 | $41,44244 claims |
| MerckJanuvia | $26 | $38,88633 claims |
| NovartisEntresto | $85 | $25,56631 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $84 | $24,38552 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $24,20141 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $256 | $22,49929 claims |
| AbbVieLinzess, Synthroid | $654 | $17,81969 claims |
| Lilly USA, LLCMounjaro | $140 | $11,49511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.
Other family in Aiken
- Dana DudleyAiken$18K
- Tina NordeenAiken$17K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.